NO20012961L - Trisykliske farnesylproteintransferase-inhibitorer - Google Patents

Trisykliske farnesylproteintransferase-inhibitorer

Info

Publication number
NO20012961L
NO20012961L NO20012961A NO20012961A NO20012961L NO 20012961 L NO20012961 L NO 20012961L NO 20012961 A NO20012961 A NO 20012961A NO 20012961 A NO20012961 A NO 20012961A NO 20012961 L NO20012961 L NO 20012961L
Authority
NO
Norway
Prior art keywords
group
protein transferase
farnesyl protein
stands
transferase inhibitors
Prior art date
Application number
NO20012961A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012961D0 (no
Inventor
Arthur G Taveras
Ronald J Doll
Alan Bruce Cooper
Johan A Ferreira
Timothy Guzi
Alan K Mallams
Dinanath F Rane
Viyyoor Moopil Girijavallabhan
Adriano Afonso
Cynthia J Aki
Jianping Chao
Carmen Alvarez
Joseph M Kelly
Tarik Lalwani
Jagdish A Desai
James J S Wang
Jay Weinstein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20012961D0 publication Critical patent/NO20012961D0/no
Publication of NO20012961L publication Critical patent/NO20012961L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20012961A 1998-12-18 2001-06-15 Trisykliske farnesylproteintransferase-inhibitorer NO20012961L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
PCT/US1999/027939 WO2000037459A1 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors

Publications (2)

Publication Number Publication Date
NO20012961D0 NO20012961D0 (no) 2001-06-15
NO20012961L true NO20012961L (no) 2001-08-16

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012961A NO20012961L (no) 1998-12-18 2001-06-15 Trisykliske farnesylproteintransferase-inhibitorer

Country Status (20)

Country Link
EP (1) EP1140902A1 (enExample)
JP (1) JP2002533336A (enExample)
KR (1) KR20010081116A (enExample)
CN (1) CN1326850C (enExample)
AR (1) AR021718A1 (enExample)
AU (1) AU776558B2 (enExample)
BR (1) BR9916314A (enExample)
CA (1) CA2354779A1 (enExample)
CO (1) CO5160350A1 (enExample)
CZ (1) CZ20011950A3 (enExample)
HU (1) HUP0202152A2 (enExample)
IL (1) IL143408A0 (enExample)
NO (1) NO20012961L (enExample)
NZ (1) NZ511878A (enExample)
PE (1) PE20001342A1 (enExample)
PL (1) PL348293A1 (enExample)
SK (1) SK7592001A3 (enExample)
TR (1) TR200101755T2 (enExample)
WO (1) WO2000037459A1 (enExample)
ZA (1) ZA200104233B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
BR112016021257B1 (pt) * 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
ZA985203B (en) * 1997-06-17 1999-01-05 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
PL348293A1 (en) 2002-05-20
IL143408A0 (en) 2002-04-21
SK7592001A3 (en) 2002-03-05
ZA200104233B (en) 2002-08-22
NZ511878A (en) 2003-10-31
CZ20011950A3 (cs) 2001-12-12
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
JP2002533336A (ja) 2002-10-08
AU776558B2 (en) 2004-09-16
HUP0202152A2 (en) 2002-10-28
CA2354779A1 (en) 2000-06-29
WO2000037459A1 (en) 2000-06-29
TR200101755T2 (tr) 2001-09-21
EP1140902A1 (en) 2001-10-10
BR9916314A (pt) 2001-10-02
CN1326850C (zh) 2007-07-18
PE20001342A1 (es) 2000-12-09
CO5160350A1 (es) 2002-05-30
AU2030700A (en) 2000-07-12
NO20012961D0 (no) 2001-06-15
CN1334811A (zh) 2002-02-06

Similar Documents

Publication Publication Date Title
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
CA2322944A1 (en) Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
DE69314456D1 (de) Arylsulfonamido-substituierte Hydroxamsäure Derivate
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
TR200101754T2 (tr) Farnezil protein transferaz inhibitörleri
CA2318145A1 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
DK1054874T3 (da) Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO963370L (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
NO964095L (no) Nye hydroksypyridinoner
NO20012961L (no) Trisykliske farnesylproteintransferase-inhibitorer
KR20050042829A (ko) 세포 유착 저해제
AU7949791A (en) Diaminotrifluoromethylpyridine derivatives, process for their production and phospholipase a2 inhibitor containing them
MXPA04004802A (es) Derivados del 1,2,4-triazol que contienen un grupo sulfamato como inhibidores de aromatasa.
NO971142L (no) Bis-(2-halogenetyl)aminofenylsubstituerte distamycinderivater som antitumor- og antivirale midler
ATE209201T1 (de) Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
EP0713877A4 (en) QINGHAOSU DERIVATIVES USED TO COMBAT AIDS
DE60108089D1 (de) Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel
EP0754454A4 (en) CHOLINESTERASE ACTIVATOR
NO991235D0 (no) Forbindelser anvendelige for inhibering av farnesylproteintransferase
DK1387841T3 (da) Hidtil ukendt azol- eller triazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som fungicider
ATE312086T1 (de) Phenoxazinanaloge zur behandlung von amyloidose
WO2000034247A3 (de) Verfahren zur herstellung von pyrazolylbenzoylderivaten sowie neue pyrazolylbenzoylderivate
ATE248831T1 (de) Benzo(5,6)cyclohepta(1,2b)pyridine derivate anwendbar als farnesyl protein transferase inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application